You need JavaScript to view this

Future of nuclear medicine

Abstract

When it comes to setting up nuclear medicine in a developing country, there is a group of people, who feel that such high technology has no place in a developing country. RIA is likely to remain the method of choice for the research laboratory. The use of radioisotopic label has many advantages compared to the use of an enzyme marker. Generally, iodination is simpler than the preparation of an enzyme labelled substance, especially since there has been no agreement as to which enzyme is best for substances as small as steroids or a large as viruses. In addition, there may be some change in the configuration of the enzyme or the substance to be labelled during the conjugation procedure. Monoclonal antibodies can provide virtually unlimited amounts of homogenous antibodies against a specific antigenic site. The heterogeneous antibodies are more likely to provide more sensitive assays than the monoclonal antibodies, although assays employing the latter are likely to be more specific. The optimal choice of the antiserum may depend on whether sensitivity or specificity is required for the assays
Authors:
Publication Date:
Dec 31, 1992
Product Type:
Technical Report
Report Number:
NMS-1
Reference Number:
SCA: 550600; PA: AIX-29:049633; EDB-98:095782; SN: 98002003669
Resource Relation:
Other Information: PBD: 1992; Related Information: Is Part Of Handbook of nuclear medicine practice in developing countries; PB: 728 p.
Subject:
55 BIOLOGY AND MEDICINE, BASIC STUDIES; COST; DEVELOPING COUNTRIES; DIAGNOSTIC TECHNIQUES; FORECASTING; NUCLEAR MEDICINE; PLANNING; RADIOPHARMACEUTICALS; TECHNOLOGY TRANSFER
OSTI ID:
640621
Research Organizations:
International Atomic Energy Agency, Vienna (Austria). Nuclear Medicine Section
Country of Origin:
IAEA
Language:
English
Other Identifying Numbers:
Other: ON: DE98635463; TRN: XA9847635049633
Availability:
INIS; OSTI as DE98635463
Submitting Site:
INIS
Size:
pp. 715-720
Announcement Date:

Citation Formats

Ganatra, R D. Future of nuclear medicine. IAEA: N. p., 1992. Web.
Ganatra, R D. Future of nuclear medicine. IAEA.
Ganatra, R D. 1992. "Future of nuclear medicine." IAEA.
@misc{etde_640621,
title = {Future of nuclear medicine}
author = {Ganatra, R D}
abstractNote = {When it comes to setting up nuclear medicine in a developing country, there is a group of people, who feel that such high technology has no place in a developing country. RIA is likely to remain the method of choice for the research laboratory. The use of radioisotopic label has many advantages compared to the use of an enzyme marker. Generally, iodination is simpler than the preparation of an enzyme labelled substance, especially since there has been no agreement as to which enzyme is best for substances as small as steroids or a large as viruses. In addition, there may be some change in the configuration of the enzyme or the substance to be labelled during the conjugation procedure. Monoclonal antibodies can provide virtually unlimited amounts of homogenous antibodies against a specific antigenic site. The heterogeneous antibodies are more likely to provide more sensitive assays than the monoclonal antibodies, although assays employing the latter are likely to be more specific. The optimal choice of the antiserum may depend on whether sensitivity or specificity is required for the assays}
place = {IAEA}
year = {1992}
month = {Dec}
}